This study compared the cardiovascular and renal effects of long-term telmisartan (3 and 10 mg/kg/day) and lisinopril (10 mg/kg/day) in an animal model combining hypertension and diabetes mellitus. It was a parallel-group study of diabetic, spontaneously hypertensive rats (SHR), treated with control or active treatment for eight months. A non-diabetic SHR control group was run in parallel. Diabetes was induced by streptozotocin (45 mg/kg i.v.) in SHRs aged 9-10 weeks. Animals were treated with telmisartan (3 or 10 mg/kg/day), lisinopril (10 mg/kg/day) or vehicle. Plasma glucose levels, blood pressure (BP), and urinary protein and albumin excretion were measured monthly. Telmisartan treatment significantly reduced BP of diabetic SHRs in a dose-dependent manner (p<0.05, low-dose, n=18; p<0.01, high-dose, n=15). The BP reduction in the lisinopril group was similar to that in the telmisartan 10 mg/kg/day group. Compared with non-diabetic SHRs, untreated diabetic SHRs developed severe proteinuria and albuminuria over the experimental period (p<0.01). In diabetic SHRs, proteinuria and albuminuria were dose-dependently and significantly attenuated by treatment with telmisartan (p<0.01 with the higher dose) and lisinopril (p<0.01). Compared with the untreated diabetic SHRs, cardiac hypertrophy was significantly reduced after treatment with both doses of telmisartan and with lisinopril. Telmisartan, 10 mg/kg/ day, but not lisinopril, significantly attenuated the diabetes-induced increase in glomerular volume. In conclusion, telmisartan, 10 mg/kg/day, is at least as beneficial as lisinopril, 10 mg/kg/day, in lowering BP, reducing cardiac hypertrophy and attenuating renal excretion of protein and albumin in this model.
Introduction
It is well established that the incidence of cardiovascular morbidity and mortality is markedly higher amongst individuals with diabetes than in non-diabetics. [1] [2] [3] This elevated risk is partially attributable to hypertension.Arterial hypertension accelerates the progression of microvascular and macrovascular complications associated with diabetes, contributing to diabetic nephropathy and, ultimately, to renal failure. Diabetic nephropathy is characterised by persistent albuminuria (>300 mg/24-hour), early blood pressure (BP) elevation, a relentless decline in glomerular filtration rate (GFR) of approximately 10-14 ml/min per year, and development of both proteinuria and albuminuria. 4 Without intervention, 30-40% of patients with Type 1 or Type 2 diabetes will develop diabetic nephropathy. 5 However, effective BP control in diabetic populations has been shown to reduce the incidence of diabetic complications. 6, 7 The nephroprotective effects of long-term treatment with an angiotensin-converting enzyme (ACE) inhibitor have been demonstrated with captopril. 8 More recent long-term studies examining the effects of long-acting dihydropyridine calcium channel blockers (CCB) and ACE inhibitors (ACE-I) in patients with diabetic nephropathy have revealed similar beneficial effects on the rate of decline in GFR. [9] [10] [11] Telmisartan (BIBR 277) is a selective angiotensin II (Ang II) AT 1 -receptor antagonist, 12 which has been approved for the treatment of hypertension. This agent has shown potent and significant antihypertensive, renoprotective and cardioprotective effects in different animal models of hypertension, including the transgenic rat TGR(mREN2)27 and stroke-prone spontaneously hypertensive rat (SHR) models. [13] [14] [15] In the stroke-prone SHR animals, telmisartan reduced albuminuria and provided effective BP control. 15 Telmisartan was also associated with a significant cardioprotective effect, unlike losartan or captopril, despite equivalent BP responses with each of the antihypertensive agents. 15 Receptor binding studies, as well as functional studies, have also demonstrated that telmisartan potently interacts with rat renal AT 1 -receptors. 16 Pre-clinical models of diabetes have not generally been associated with significant hypertension. To evaluate the role of hypertension in the evolution of diabetic nephropathy, we have used a hypertensive, diabetic model that combines genetic hypertension (SHR) with streptozotocin-(STZ) induced diabetes (the STZ-SHR model). 17, 18 Therefore, the present study was designed to investigate the antihypertensive, renoprotective and cardioprotective effects of telmisartan after long-term treatment in a rat model that combined both diabetes and hypertension.The activity of telmisartan was compared with that of the ACE-I, lisinopril.
Methods

Study design
Male SHRs (Okamoto strain) were aged 9-10 weeks on the day of administration of STZ. Diabetes was induced by a single dose of STZ (45 mg/kg i.v., SIGMA), in 2 ml/kg of 0.1 M sodium citrate buffer, pH 4.5, seven days prior to the antihypertensive treatment period. The normoglycaemic SHR control animals received vehicle only. One day prior to the start of the treatment, all animals were randomised and those with less than 20 mmol/l blood glucose were excluded from the study.
The study protocol included five experimental groups: untreated, normoglycaemic SHR, which served as a hypertensive control group (n=12); untreated, STZ-SHR (n=22) which served as a diabetic, hypertensive control group; STZ-SHR, treated with telmisartan at a daily dose of 3 mg/kg (n=22); STZ-SHR, treated with telmisartan at a daily dose of 10 mg/kg (n=22) and STZ-SHR, treated with lisinopril at a daily dose of 10 mg/kg (n=22). The doses were chosen to achieve equivalent antihypertensive efficacy with the higher dose of telmisartan and the given dose of lisinopril. On the basis of haemodynamics, it is essential to compare renoprotective effects of the two drugs, especially with respect to albumin excretion, against a background of equal BP reduction.
The treatment period lasted 32 weeks, during which animals did not receive insulin support. Drug doses were adjusted for body weight and were administered daily in a solution of hydroxyethylcellulose, 0.5%, by gavage, via a cannula of the appropriate dimensions. Animals in the two control groups received vehicle only.
Experimental parameters
Baseline measurements were taken of body weight, BP, heart rate, plasma glucose and creatinine. Systolic blood pressure (SBP) and heart rate were measured using the tail-cuff method (APELEX BP recorder), after an acclimatisation period of 30 minutes in a restraint cage.The mean of three successive measurements was recorded. Urinary volume, total urinary protein (COBAS MIRA-S [ROCHE] analyser), albumin (MRX DYNATECH LABORATORY using competitive ELISA), creatinine, glucose and electrolyte (chloride, sodium, potassium) excretion were determined over a 24-hour period in a diuresis cage (IFFA CREDO). Urinary albumin, total urinary protein, potassium and sodium results were determined as the concentration in the urine sample (mg/ml and µmol/ml, respectively) and calculated as urinary excretion (mg/24-hour and µmol/24hour, respectively) over 24 hours. Levels of creati-nine and glucose were also measured in blood plasma samples. All parameters were examined every four weeks during the entire experimental period, except for body weight, which was checked on a weekly basis in order to adjust drug dosages.
All animals were sacrificed at the end of the treatment period and underwent post-mortem examinations. Tissues were perfused with a fixative solution (0.05 M Na-Cacodylate buffer pH 7.4, 343 mOsm including 2% glutaraldehyde, 5 mg tannic acid/ml, 1 ml CaCl 2 /ml and 1 mg MgCl 2 /ml). The kidneys, heart, liver and lungs of each animal were weighed, fixed, sectioned and embedded in paraffin wax for histological examination by light microscopy. Kidney sections (2 µm) were stained with haematoxylin/eosin or by the periodic acid Schiff method. The mean glomerular tuft volume (V G ) was assessed for each animal using an established technique. 19 The glomerular cross-sectional area (A G ) was determined on 50 systematically-sampled glomerular tuft profiles by the automatic image analysis method (Quantimet 500 MC-LEICA).A glomerular profile was defined as the minimal convex polygon circumscribing the capillary tuft. V G was calculated as b/K (A G ) 3/2 where β = 1.38 and K = 1.1 are shape and size distribution coefficients, respectively. Tissue was evaluated semi-quantitatively for glomerular basement membrane thickness, mesangial expansion, glomerular volume, glomerulosclerosis and other diabetic or hypertensive changes.
Statistical analysis
Results are given as mean values±SEM. Regarding urinalysis, the GFR was calculated from the creatinine clearance as follows: GFR = (U creatinine x V)/P creatinine , where U = urinary concentration (µmol/l); P = plasma concentration (µmol/l) and V = urinary volume (ml/min/kg of body weight).
The differences between the groups with respect to the cardiovascular and biochemical parameters were evaluated using one-way analysis of variance (ANOVA) for repeated measurements, followed by a Newman-Keuls test in case of significance (p<0.05). Glomerular volume was evaluated as median values and statistical significance determined by a Mann-Whitney non-parametric U-test.
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PAPER Table 1 Body weight, systolic blood pressure and biochemical parameters (mean±SEM) in the five experimental groups on Day 1 prior to first dosing with antihypertensive therapy (baseline). SBP = systolic blood pressure; SHR = spontaneously hypertensive rat; STZ-SHR = streptozotocin-induced diabetes in spontaneously hypertensive rat model; *= p<0.05 vs. hyperglycaemic SHR control group 
Results
The treatment groups were not different from one another in terms of body weight, arterial pressure, glycaemia, or plasma creatinine measured at Day 1 by one-way ANOVA (see Table 1 for baseline parameters). However, compared with the normoglycaemic SHR, the corresponding body weight was significantly reduced and plasma glucose levels were significantly higher in the hyperglycaemic SHR.
Changes between normoglycaemic SHR and hyperglycaemic STZ-SHR untreated controls
A summary of the selected clinical and clinicopathological parameters at the completion of the 32-week treatment period is given in Table 2 . As anticipated, body weight gain was markedly attenuated following STZ administration in STZ-SHR controls, but continued normally in the nondiabetic SHR controls. Throughout the 32-week treatment period, animals in the control STZ-SHR group weighed less than the normoglycaemic control SHR group (p≤0.01). From Month 1 of the treatment period onwards, plasma and urine glucose, urine volume and GFR were significantly higher in untreated STZ-SHR animals than in their normoglycaemic SHR counterparts (p≤0.01). In contrast, STZ-SHR controls had significantly lower urinary creatinine levels than the SHR controls (p≤0.01), which can be attributed to the greatly diluted urine in the former animals. However, 24-hour creatinine excretion was higher in the untreated STZ-SHR group than the SHR control group.
Both urinary total protein excretion and urinary albumin excretion increased progressively in the untreated STZ-SHR compared with the nondiabetic controls, reaching significance beyond five and three months respectively (p≤0.05). Mean BP in the STZ-SHR control group remained high during the study period and was not different from the normoglycaemic SHR (p>0.05).
Effect of antihypertensive treatment on BP
The effects of long-term antihypertensive treatment with telmisartan (3 and 10 mg/kg/day) and lisinopril (10 mg/kg/day) on SBP in diabetic SHR are shown in Figure 1 and Table 2 . Long-term oral treatment with telmisartan significantly decreased SBP in a dose-and time-dependent manner to 162±6 and 153±6 mmHg for the 3 and 10 mg/kg/day doses, respectively.
PAPER Table 2 Body weight, blood pressure and biochemical parameters (mean±SEM) in the five experimental groups at the end of the 32-week treatment period. SBP = systolic blood pressure; SHR = spontaneously hypertensive rat; STZ-SHR = streptozotocin-induced diabetes in spontaneously hypertensive rat model; * = p≤0.05, ** = p≤0.01 vs. hyperglycaemic SHR control group Significant reductions in SBP from baseline values were observed with all treatments after Month 1 (p≤0.01 with telmisartan 10 mg/kg/day and lisinopril 10 mg/kg/day; p≤0.05 with telmisartan 3 mg/ kg/day). The reduction in SBP with 10 mg/kg/day telmisartan was comparable to that observed in the lisinopril group.
Effect of antihypertensive treatment on urinary protein excretion
The effect of long-term antihypertensive treatment with telmisartan and lisinopril on urinary protein excretion in this animal model is shown in Figure 2 . Treatment with telmisartan (at both doses) and lisinopril attenuated the slow but progressive increase in urinary protein excretion seen in the untreated STZ-SHR animals towards the end of the study period. 
Effect of antihypertensive treatment on urinary albumin excretion
The effect of long-term antihypertensive treatment with telmisartan and lisinopril on urinary albumin excretion is shown in Figure 3 .Treatment with telmisartan and lisinopril slowed the progression of urinary albumin excretion to 7.8±1.9 mg/24-hour (telmisartan 10 mg/kg/day; p≤0.01) and 6.7±1.4 mg/24-hour (lisinopril 10 mg/kg/day; p≤0.01) at the end of the treatment period compared with 23.8±5.2 mg/24-hour in the untreated STZ-SHR animals. The effect of telmisartan was dose-dependent.
Effect of antihypertensive treatment on body weight and heart rate
Mean body weights and heart rates in animals receiving 32 weeks of active antihypertensive PAPER Figure 2 Effect of long-term oral antihypertensive treatment with telmisartan and lisinopril on urinary protein excretion in diabetic SHRs.Values are given as mean±SEM.
Figure 3
Effect of long-term oral antihypertensive treatment with telmisartan and lisinopril on urinary albumin excretion in diabetic SHRs.Values are given as mean±SEM. treatment were not significantly different from those of the untreated STZ-SHR control group (p>0.05). Similarly, plasma and urinary glucose, urinary volume and GFR were also unaffected by the antihypertensive agents.
Effect of antihypertensive treatment on organ weights
The relative weights of all of the organs studied, except that of the right ventricle, were significantly reduced in the hyperglycaemic STZ-SHR control animals compared with the normoglycaemic SHR controls.Treatment with telmisartan and lisinopril had no significant effect on relative or absolute weights of kidneys, heart, right ventricle, lungs or liver when compared with the STZ-SHR control group. However, a statistically significant decrease in the weight of the left ventricle was apparent ( Table 3) .
Histology
Glomerular basement membrane thickness, mesangial expansion and glomerulosclerosis were not significantly altered by any treatment (results not shown). However, calculation of the glomerular tuft volume, V G , through histological analysis, showed that diabetes was associated with a significant increase in this parameter compared with non-diabetic controls (2.68 vs. 2.37 [µm 3 (x10 6 )]; p≤0.05). Treatment with telmisartan, 10 mg/ kg/day, but not lisinopril significantly (p<0.05) attenuated V G in STZ-SHR animals (Figure 4 ).
Discussion
Telmisartan has demonstrated potent antihypertensive and nephroprotective effects in different rat models of hypertension. [13] [14] [15] The present study confirmed and extended this antihypertensive efficacy of telmisartan to a rat model combining essential hypertension (SHR) with Type 1 diabetes.At the higher dosage, (10 mg/kg/day), telmisartan and lisinopril reduced systolic arterial pressure in diabetic SHR in a dose-dependent manner to almost normotensive values. In addition, the progressive increase in urinary protein and albumin excretion observed in untreated diabetic SHR was dose-dependently inhibited by long-term treatment with telmisartan and lisinopril. With the higher dose of telmisartan and with lisinopril, these parameters were almost reduced to values observed in the normoglycaemic SHRs. Ang II acts preferentially on AT 1 -receptors in the efferent arterioles in the kidney,which leads to an increase in the transglomerular pressure gradient. 20 Blockade of these receptors is therefore associated with a reduction in the transglomerular pressure gradient and hence a reduction in the filtration pressure for macromolecules. This, in concert with a general reduction in SBP, may account for the significant decrease in urinary protein excretion. It has been shown previously, in hypertensive transgenic rats, that telmisartan was able to prevent urinary albumin excretion even at a dose which did not significantly lower systemic BP, but may well affect glomerular pressure. 13 Telmisartan is known to potently interact with rat renal glomerular AT 1 -receptors. 16 Therefore, the antiproteinuric and antialbuminuric effects of telmisartan in hypertensive diabetic rats may also be ascribed, at least in part, to a reduction in the intraglomerular pressure.
Histological analysis also revealed that treatment with telmisartan, 10 mg/kg/day, reduced glomerular volume, suggesting structural protective effects at the level of the glomeruli.
The increase in GFR observed from Month 1 after STZ administration reflects an impairment of renal function following the substantial increase in urine output.The absence of effect of any of the antihypertensive agents on this parameter suggests that GFR is less sensitive than urinary total protein and albumin excretion as an indicator of renal protection in this animal model.
The difference in left ventricular weight between STZ-SHR controls and animals treated with antihypertensive agents was probably due to a partial reversal of the left ventricular hypertro- phy that is associated with this model combining diabetes and hypertension. 21 Similarly, regression in cardiac myocyte hypertrophy has been shown in hypertensive rats after long-term telmisartan treatment. 12 The present study also demonstrates a cardioprotective effect after long-term treatment with telmisartan or lisinopril. Induction of diabetes in rats by STZ administration is a common animal model of Type 1 diabetes.The model is characterised by reduced body weight gain, an increase in plasma and urine glucose levels, and increases in urine volume and GFR.The data in this study are in accordance with these effects. Long-term treatment with either telmisartan or lisinopril did not modify body weight and these respective biochemical parameters.This is also in agreement with reports in the literature using either the ACE-I perindopril 22 or the Ang II AT 1 -receptor antagonist losartan. 23 In addition, it could be confirmed that diabetes exacerbates renal injury and accelerates nephropathy in hypertensive SHR. 17, 18 Despite similar blood pressure values in the normoglycaemic and the diabetic SHR, proteinuria and albuminuria developed more rapidly and to a much greater extent in the latter.
Comparisons between the antihypertensive properties of telmisartan and lisinopril in clinical studies have shown telmisartan to be at least as effective as the ACE-I,with a marked improvement in tolerability. 24, 25 The data from the present study suggest that this Ang II receptor antagonist may also confer valuable renoprotective and cardioprotective effects. Since inhibition of the renin-angiotensinaldosterone system with ACE-I affords protection in patients with diabetic nephropathy, 8, [26] [27] [28] it is possible that Ang II antagonists (which also act on the renin-angiotensin cascade) may confer similar clinical advantages in these patients.
In conclusion, this study demonstrates that the Ang II receptor antagonist telmisartan exerts dosedependent antihypertensive, renoprotective and cardioprotective effects in hypertensive diabetic rats, which are equivalent to those conferred by the ACE-I, lisinopril.
